Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 15 | SFEBES2008 | Next issue

Society for Endocrinology BES 2008

Oral Communications

Young Endocrinologist prize session

ea0015oc1 | Young Endocrinologist prize session | SFEBES2008

Clinical manifestations of familial paraganglioma and phaeochromocytomas in succinate dehydrogenase B gene mutation carriers

Srirangalingam Umasuthan , Walker Lisa , Khoo Bernard , MacDonald Fiona , Gardner Daphne , Wilkin Terence J , Skelly Robert H , George Emad , Spooner David , Monson John P , Grossman Ashley B , Akker Scott A , Pollard Patrick J , Plowman Nick , Avril Norbert , Berney Dan M , Burrin Jacky M , Reznek Rodney , Ajith Kumar VK , Maher Eamonn R , Chew Shern L

Background: Phaeochromocytomas and paragangliomas are familial in up to 25% of cases and can result from succinate dehydrogenase (SDH) gene mutations.Objective: To describe the clinical manifestations of subjects with SDH-B gene mutations.Design: Retrospective case series.Patients: Thirty-two subjects with SDH-B gene mutations followed-up between 1975 and 2007. Mean follow-up of 5.8 years (S.D....

ea0015oc2 | Young Endocrinologist prize session | SFEBES2008

The ghrelin-cannabinoid axis: a novel pathway in the regulation of appetite and metabolism

Amin Faisal , Kola Blerina , Christ-Crain Mirjam , Lolli Francesca , Wittmann Gabor , Harvey-White Judith , Kunos George , Grossman Ashley B , Fekete Csaba , Korbonits Marta

We have previously shown that the orexigenic and peripheral adipogenic effects of ghrelin are mediated by its effect on the metabolic enzyme AMPK. As the cannabinoid (CB1)-antagonist rimonabant inhibits the orexigenic effect of ghrelin, we suggest that there is an interaction between cannabinoids and ghrelin.To study the involvement of CB1 in the effects of ghrelin, wild-type (WT) and CB1-knockout mice were treated with ghrelin and rimonabant.<p clas...

ea0015oc3 | Young Endocrinologist prize session | SFEBES2008

Does 11βHSD1 in visceral adipose tissue (VAT) deliver cortisol to the liver? Studies with portal vein sampling and tracer infusion in humans

Stimson Roland , Andrew Ruth , Redhead Doris , Hayes Peter , Walker Brian

Cortisol is regenerated from cortisone by 11βHSD1 reductase in cells from VAT. Mice overexpressing 11βHSD1 in adipocytes have more glucocorticoids in the portal vein (PV) and hepatic insulin resistance. In humans, hepatic vein (HV) sampling during D4-cortisol tracer infusion confirmed substantial splanchnic cortisol generation, and indirect modelling suggested major contributions from both liver and VAT. PV sampling in dogs, however, did not reveal cortisol release f...

ea0015oc4 | Young Endocrinologist prize session | SFEBES2008

Hypoxia and GC Signalling regulate macrophage migration inhibitory factor (mif) gene expression through a common element

Elsby Laura , Donn Rachelle , Alourfi Zaynab , Beaulieu Elaine , Ray David

MIF is a potent pro-inflammatory mediator that opposes the anti-inflammatory actions of glucocorticoids (Gc) and is involved in the pathogenesis of multiple diseases. The MIF promoter is inhibited by Gc in lymphocytes (CEMC7A) but not in epithelial cells (A549), despite expression of functional glucocorticoid receptors (GR) in both. Deletion studies localized the cis element responsible for Gc inhibition to between MIF −71 and +85. This sequence contained no GR binding s...

ea0015oc5 | Young Endocrinologist prize session | SFEBES2008

Placental vascular development and nutrient transport in 11β-HSD2−/− mice

Wyrwoll Caitlin , Seckl Jonathan , Holmes Megan

Fetal glucocorticoid exposure is a key mechanism involved in adverse programming outcomes in the adult, including hypertension, anxiety and insulin resistance. While glucocorticoids may exert their effects directly on the fetus, they may also affect fetal growth through indirect effects on placental function. Regulation of fetal glucococorticoid exposure is achieved by the placental glucocorticoid barrier, which involves glucocorticoid inactivation within the labyrinth zone of...

ea0015oc6 | Young Endocrinologist prize session | SFEBES2008

MRAP2 permits the functional expression of the melanocortin-2-receptor: a new member of a new family of melanocortin receptor accessory proteins

Chan Li , Metherell Louise , Elphick Maurice , Chapple J Paul , Clark Adrian

Background: The identification of MRAP in 2005 as the first melanocortin-2-receptor (MC2R)/ACTH receptor accessory protein provided insight into the regulation of the melanocortin receptor system. Mutations in MRAP cause Familial glucocorticoid deficiency, an autosomal recessive disorder resulting in isolated cortisol deficiency. In vitro studies showed that MRAP was essential for the functional expression of the MC2R. The melanocortin receptor (MCR) family (MC1R to MC5...

ea0015oc7 | Young Endocrinologist prize session | SFEBES2008

Testosterone treatment improves muscle strength, lean mass and quality of life in prefrail and frail elderly men: results from a randomised double-blind placebo-controlled study

Srinivas-Shankar Upendram , Roberts Stephen A , Adams Judith E , Connolly Martin J , Oldham Jackie A , Wu Frederick CW

Introduction: Testosterone (T) improves muscle strength in hypogondal men. It is unclear if testosterone has similar effects in prefrail and frail elderly men with low T. We conducted a randomised double-blind placebo-controlled parallel group study to determine the effects of T on muscle mass and strength, physical function and quality of life in prefrail and frail elderly men.Methods: Two hundred and sixty two prefrail and frail elderly men (Fried e...

ea0015oc8 | Young Endocrinologist prize session | SFEBES2008

β-cell 11β-Hydroxysteroid dehydrogenase type 1 contributes to type 2 diabetes

Turban Sophie , Ramage Lynne , Paterson Janice , Mullins John , Seckl Jonathan , Morton Nik

High systemic cortisol levels contribute to insulin resistance and may exacerbate the development of diabetes by impairing the insulin secretory response of the pancreatic beta-cells (β-cells). 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) is a key modulator of glucocorticoid effect within target tissues and high adipose or liver levels of this enzyme may contribute to obesity and/or metabolic disease. We investigated cellular localization of 11β-HSD1 ...